FTY720 and cladribine filing info
Posted: Mon Nov 09, 2009 11:42 pm
http://www.reuters.com/article/Health09 ... WY20091109
excerpt from the above article
Jimenez said the lower dose of oral multiple sclerosis drug FTY720, which Novartis plans to file with regulators next month, was "clearly approvable" and would be an attractive option for patients seeking an alternative to injections.
It is in a head-to-head race with Merck KGaA's (MRCG.DE: Quote, Profile, Research, Stock Buzz) cladribine to be the first oral MS drug on the market and the German group has stolen a march having already filed for approval in the United States.
TOL
excerpt from the above article
Jimenez said the lower dose of oral multiple sclerosis drug FTY720, which Novartis plans to file with regulators next month, was "clearly approvable" and would be an attractive option for patients seeking an alternative to injections.
It is in a head-to-head race with Merck KGaA's (MRCG.DE: Quote, Profile, Research, Stock Buzz) cladribine to be the first oral MS drug on the market and the German group has stolen a march having already filed for approval in the United States.
TOL